期刊文献+

PD-1/PD-L1抑制性信号通路在宫颈癌发生发展中的临床意义 被引量:11

Clinical Significance of PD-1/PD-L1 Inhibitory Signaling Pathway in the Development of Cervical Cancer
下载PDF
导出
摘要 目的探讨PD-1/PD-L1抑制性信号通路在宫颈癌发生发展中的生物学作用机制及其临床意义。方法采集60例宫颈癌患者的新鲜肿瘤组织标本,40例宫颈上皮内瘤样病变组织(CIN),另采集20位健康者宫颈组织标本,运用相关免疫法检测3种组织及外周血中PD-1/PD-L1的表达水平。结果 PD-1在宫颈癌组及CIN组中的表达均高于健康组,差异有统计学意义(χ~2=37. 921,P=0. 002;χ~2=5. 382,P=0. 021);宫颈癌组PD-1表达远高于CIN组,差异有统计学意义(χ~2=21. 639,P=0. 005)。PD-L1在宫颈癌组及CIN组中的表达均高于健康组,差异有统计学意义(χ~2=41. 462,P=0. 000;χ~2=29. 834,P=0. 003);宫颈癌组PD-L1表达高于CIN组,但差异无统计学意义(χ~2=0. 271,P=0. 579)。PD-1在CD4^+T及CD8^+T细胞中的表达宫颈癌组及CIN组远高于健康组,差异有统计学意义(P <0. 05),且宫颈癌组远远高于CIN组,组间比较差异有统计学意义(P <0. 05)。宫颈癌组织中PD-1/PD-L1表达与患者年龄、病灶直径、HPV是否感染无明显关系(P>0. 05),与癌细胞的分化程度和FIGO分期有关(P <0. 05);癌间质及癌细胞中,PD-1/PD-L1表达均无相关性。结论 PD-1/PD-L1抑制通路促进宫颈癌的发生、发展,两者结合抑制机体免疫功能正常应答,使癌细胞得以逃脱机体免疫系统的监控和杀灭。 Objective To investigate the inhibition of PD-1/PD-L1 signaling pathway in cervical cancer biology mechanism in the development and its clinical significance.Methods For treatment of 60 cases of cervical cancer patients with fresh tumor tissue specimens,40 cases of cervical intraepithelial neoplasia(CIN),the other 20 healthy persons collected cervical tissue samples,the expression level of PD-1 was detected by immune 3 kinds of tissues and peripheral blood/PD-L1.Results The expression of PD-1 in cervical cancer group and CIN group was higher than that in healthy group,the difference was statistically significant(χ~2=37.921,P=0.002;χ~2=5.382,P=0.021);PD-1 expression in cervical cancer group was far Above the CIN group,the difference was statistically significant(χ~2=21.639,P=0.005).The expression of PD-L1 in cervical cancer group and CIN group was higher than that in healthy group,the difference was statistically significant(χ~2=41.462,P=0.000;χ~2=29.834,P=0.003);high expression of PD-1 in cervical cancer group In the CIN group,the difference was not statistically significant(χ~2=0.271,P=0.579).The expression of PD-1 in CD4^+T and CD8^+T cells was significantly higher in the cervical cancer group and CIN group than in the healthy group(P<0.05),and the cervical cancer group was much higher than the CIN group.The difference between the two groups was statistically significant(P<0.05).There was no significant relationship between the expression of PD-1/PD-L1 in cervical cancer tissues and the age,lesion diameter and HPV infection(P>0.05).Conclusion PD-1/PD-L1 inhibition pathway promotes the occurrence and development of cervical cancer.The combination of them inhibits the normal response of immune function,and makes the cancer cells escape from the monitoring and killing of the immune system.
作者 刘贝贝 董枫 LIU Beibei;DONG Feng(Zhengzhou People's Hospital,Zhengzhou,450000)
出处 《实用癌症杂志》 2019年第4期546-549,共4页 The Practical Journal of Cancer
关键词 PD-1/PD-L1 抑制信号通路 宫颈癌 PD-1/PD-L1 Inhibition of signaling pathway Cervical cancer
  • 相关文献

参考文献12

二级参考文献49

  • 1Pedoeem A, Azoulay A I, Strazza M, et al. Programmed death- 1 pathway in cancer and autoimmunity[J ]. Clin Immunol, 2014, 153 ( 1 ): 145-152.
  • 2Fuller MJ, Callendret B, Zhu B, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against pro- grammed cell death-1 (PD-1) [J]. Proc Natl Acad Sci USA, 2013, 110 (37): 15001-15006.
  • 3Han Y, Li J, Jiang L, et al. Regulation of B7-H1 expression on peripheral monocytes and ifn-gamma secretion in T lymphoeytes by hbeag[J]. Cell Immunol,2013, 283 (1-2): 25-30.
  • 4Chang DY, Song SH, You S, et al. Programmed death-1 (PD- 1 )-dependent functional impairment of CD^4+ Cells in recur- rent genital papilloma[J]. Clin Exp Med,2014,14(3): 305-313.
  • 5Dawn E,Dolan P, Shilpa G.PD-1 pathway inhibitors:changing the landscape of cancer immunotherapy [J]. Cancer Control, 2014, 21(3): 231-237.
  • 6Jurado JO, Alvarez IB, Pasquinell V, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effec- tor functions during human tuberculosis [J]. J lmmunol, 2008, 181 (1): 116-125.
  • 7Mamalis A, Garcha M, Jagdeo J, et al. Targeting the PD-1 pathway: a promising future for the treatment of melanoma[J]. Arch Dermatol Res ,2014, 306(6): 511-519.
  • 8Hatam LJ, Devoti JA, Rosenthal DW, et al. Immune suppres- sion in premalignant respiratory papillomas: enriched functional CD4*Foxp^3+ regulatory T cells and PD-1/PD-L1/L2 expression [J]. Clin Cancer Res,2012, 18 (7): 1925-1935.
  • 9Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and au- toimmune responses[Jl. Eur J Immunol,2003, 33 (10): 2706- 2716.
  • 10Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tol- erance and autoimmunity[J]. Immunol Rev, 2010,236:219-242.

共引文献151

同被引文献112

引证文献11

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部